Today: 20 March 2026
Subscribe
Browse Category

LSE:GSK.L 28 November 2025 - 2 March 2026

Why GSK stock is moving today: Exdensur EU nod and a fresh buyback

Why GSK stock is moving today: Exdensur EU nod and a fresh buyback

GSK shares rose 1.1% to 2,263 pence after the European Commission approved its twice-yearly asthma drug Exdensur and the company launched a new tranche of share buybacks. GSK will repurchase up to £0.45 billion in shares by April 24. The company also reported new real-world data showing its RSV vaccine Arexvy was 75.6% effective against RSV-related hospitalisation in adults over 60.
18 February 2026
··
GSK stock price in focus before London open after China starts Arexvy review

GSK stock price in focus before London open after China starts Arexvy review

China’s Center for Drug Evaluation has accepted GSK’s Arexvy RSV vaccine application for review, with a decision expected in 2027. GSK shares closed Tuesday up 0.42% at 2,168 pence ahead of the London open. JPMorgan raised its target price to £22.50, and the company’s next dividend goes ex-dividend on Feb. 19. Non-executive director Hal Barron sold 67,602 ADSs at $59.17 on Feb. 5.
11 February 2026
·
GSK stock slips in London as hepatitis B drug details awaited; Feb 4 results loom

GSK stock slips in London as hepatitis B drug details awaited; Feb 4 results loom

GSK shares slipped 0.6% to 1,879.5p in London by 10:50 GMT as investors awaited detailed data from its phase III hepatitis B drug trial. Analysts pressed for cure rate and durability figures after GSK withheld specifics. A royalty dispute over cancer drug Jemperli is pending in U.S. court, with a trial set for July 2026. Investors are watching for updates at the Jan. 13 J.P. Morgan conference and Feb. 4 results.
9 January 2026
···
Most Active UK Stocks Today (9 December 2025): BP, Barclays, Rolls‑Royce, Unilever and More in Focus

Most Active UK Stocks Today (9 December 2025): BP, Barclays, Rolls‑Royce, Unilever and More in Focus

The FTSE 100 closed down 0.2% at 9,645.09 on Monday, with heavy trading concentrated in BP, Barclays, Rolls-Royce, Unilever, Lloyds, HSBC, London Stock Exchange Group, Anglo American, GSK, and British American Tobacco. Investors pulled back ahead of key US Federal Reserve and Bank of England rate decisions. FTSE 100 futures hovered near 9,657 early Tuesday, with technical signals pointing to caution.
9 December 2025
···········
Best UK Stocks to Buy Today (8 December 2025): 7 FTSE 100 Ideas for a Potential Rate‑Cut Era

Best UK Stocks to Buy Today (8 December 2025): 7 FTSE 100 Ideas for a Potential Rate‑Cut Era

The FTSE 100 closed near 9,660 on December 8, posting a total return of about 20–23% year-to-date, its best run since 2009. The Bank of England has held rates at 4% since August, with inflation at 3.6%. Markets expect a rate cut to 3.75% at the December 18 meeting. UK mortgage rates have dropped to their lowest since before September 2022.
8 December 2025
·········
GSK plc Stock Today, 28 November 2025: Buybacks, ‘Hold’ Ratings and Pipeline Momentum Keep Shares Near Highs

GSK plc Stock Today, 28 November 2025: Buybacks, ‘Hold’ Ratings and Pipeline Momentum Keep Shares Near Highs

GSK shares traded near 12-month highs on November 28, 2025, with London shares at 1,806p, up 0.2%, and New York ADRs at $48.02, just below their yearly peak. MarketBeat issued a fresh “Hold” consensus from seven analysts, with an average 12-month price target of $44.13, under current levels. The stock’s recent gains follow continued share buybacks and a busy drug pipeline.
28 November 2025
··

Stock Market Today

  • Eton Pharmaceuticals Q4 Earnings Miss Estimates; Shares Up 12.5% in 2025
    March 19, 2026, 7:14 PM EDT. Eton Pharmaceuticals (ETON) reported Q4 earnings of $0.05 per share, falling short of the Zacks Consensus Estimate of $0.12 and marking a 58.33% negative earnings surprise. Revenue rose to $21.28 million, a 4.22% beat over expectations and a significant increase from $11.65 million a year earlier. Despite missing earnings, shares have gained 12.5% year-to-date, outperforming the S&P 500's 3.2% decline. The company maintains a Zacks Rank #3 (Hold), signaling expected market-aligned performance. Analysts highlight that future stock moves hinge on management guidance and upcoming earnings estimate revisions amid a mixed outlook in the Medical - Biomedical and Genetics industry.
Go toTop